Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

EGFR and some of the cognate ligands extensively traffic in extracellular vesicles (EVs) from different biogenesis pathways. EGFR belongs to a family of four homologous tyrosine kinase receptors (TKRs). This family are one of the major drivers of cancer and is involved in several of the most frequen...

תיאור מלא

מידע ביבליוגרפי
Main Authors:	Zanetti-Domingues, LC, Martin-Fernandez, ML, Huber, V
פורמט:	Journal article
שפה:	English
יצא לאור:	MDPI 2020

פריטים דומים

Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles
מאת: Laura C. Zanetti-Domingues, et al.
יצא לאור: (2020-11-01)

Cooperation and interplay between EGFR signalling and extracellular vesicle biogenesis in cancer
מאת: Zanetti-Domingues, LC, et al.
יצא לאור: (2020)

Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer
מאת: Laura C. Zanetti-Domingues, et al.
יצא לאור: (2020-12-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
מאת: Xu H, et al.
יצא לאור: (2019-07-01)

Extracellular Vesicles As Mediators of Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Preclinical Models
מאת: M. Pérez-Capó, et al.
יצא לאור: (2023-11-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
מאת: Lihua Huang, et al.
יצא לאור: (2015-09-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
מאת: Lu Yang, et al.
יצא לאור: (2022-06-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
מאת: Yao Li, et al.
יצא לאור: (2024-12-01)

HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles
מאת: J.-H. Lee, et al.
יצא לאור: (2018-02-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
מאת: Cornelius Hempel, et al.
יצא לאור: (2017-01-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
מאת: Igor Makhlin, et al.
יצא לאור: (2019-11-01)

An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation
מאת: Katri Vaparanta, et al.
יצא לאור: (2022-11-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
מאת: Tasia Amelia, et al.
יצא לאור: (2022-01-01)

Extracellular vesicle-associated tyrosine kinase-like orphan receptors ROR1 and ROR2 promote breast cancer progression
מאת: Barnabas Irmer, et al.
יצא לאור: (2023-07-01)

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
מאת: Aude I. Ségaliny, et al.
יצא לאור: (2015-03-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
מאת: Panupong Mahalapbutr, et al.
יצא לאור: (2024-02-01)

Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer
מאת: Ramya Lakshmi Rajendran, et al.
יצא לאור: (2021-02-01)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
מאת: Shannon S. Zhang, MD, et al.
יצא לאור: (2022-08-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
מאת: Kenichi Suda, et al.
יצא לאור: (2021-06-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
מאת: Xingyuan Li, et al.
יצא לאור: (2023-10-01)

Mechanisms of receptor tyrosine kinase activation in cancer
מאת: Zhenfang Du, et al.
יצא לאור: (2018-02-01)

Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
מאת: Kinlin L Chao, et al.
יצא לאור: (2012-01-01)

Action Mechanisms of Small Extracellular Vesicles in Inflammaging
מאת: Rocío Mato-Basalo, et al.
יצא לאור: (2022-04-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
מאת: Marcin Skrzypski, et al.
יצא לאור: (2017-09-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
מאת: Keigo Kobayashi
יצא לאור: (2023-12-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
מאת: Daniel B Costa, et al.
יצא לאור: (2007-10-01)

EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis
מאת: Xuedi Zhang, et al.
יצא לאור: (2022-11-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
מאת: Zhe Zhang, et al.
יצא לאור: (2019-11-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
מאת: Tim Fischer, et al.
יצא לאור: (2018-01-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
מאת: K. K. Laktionov, et al.
יצא לאור: (2019-06-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
מאת: Tatsuki Shibuta, et al.
יצא לאור: (2022-06-01)

Proteolytic Cleavage of Receptor Tyrosine Kinases
מאת: Hao Huang
יצא לאור: (2021-04-01)

Receptor Tyrosine Kinases — Expanding Horizons
מאת: Sassan Hafizi
יצא לאור: (2014-06-01)

Extracellular phosphorylation of a receptor tyrosine kinase controls synaptic localization of NMDA receptors and regulates pathological pain.
מאת: Kenji Hanamura, et al.
יצא לאור: (2017-07-01)

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
מאת: Ichiro N. Maruyama
יצא לאור: (2014-04-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
מאת: Jihene Elloumi-Mseddi, et al.
יצא לאור: (2013-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
מאת: Nathaniel J. Myall, MD, et al.
יצא לאור: (2025-02-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
מאת: D. D. SAKAEVA
יצא לאור: (2017-06-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
מאת: Soomin Kim, et al.
יצא לאור: (2025-02-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
מאת: Wu Z, et al.
יצא לאור: (2019-10-01)